Orion Pharma is the pharmaceutical business of Orion Corporation, Finland’s largest pharmaceutical company, founded in 1917, headquartered in Espoo and listed on Nasdaq Helsinki. It markets Orion’s human and veterinary medicines in Portugal through a registered local affiliate, Orionfin, Unipessoal Lda (NIF 508907365), at Avenida da República 6 in Lisbon.
Orion’s presence in Portugal is formalised through Orionfin, Unipessoal Lda, a registered Portuguese affiliate with tax number 508907365 and offices at Avenida da República 6 in central Lisbon. The local entity gives the Finnish group a direct commercial footing with Portuguese prescribers, hospitals and pharmacies rather than a pure export or distributor relationship — the structure a research-based pharmaceutical company needs to run market access, pharmacovigilance and medical affairs in-country.
The parent is a heavyweight of Finnish industry: founded in 1917, Orion Corporation is Finland’s largest pharmaceutical company, developing, manufacturing and marketing human and veterinary medicines and active pharmaceutical ingredients. Its best-known franchises internationally include the Easyhaler® dry-powder inhaler platform for respiratory disease, hospital intensive-care sedation, and an oncology pipeline developed with global partners.
Healthcare and life sciences are an underreported strand of the Nordic–Portugal corridor next to energy and retail, yet the pattern is consistent: Nordic pharma groups — Danish, Swedish and Finnish alike — maintain lean, registered Lisbon affiliates that plug Portugal into their European commercial networks. A century-old Finnish pharma with its own Portuguese NIF is exactly the kind of durable, verifiable corridor tie this directory exists to document.
Fractio helps Nordic companies enter and scale in Portugal and Iberia — with local presence, without the overhead.
Talk to Fractio →